Home > Knowledge > Content
Elderly medication
Sep 20, 2017

In the clinical trials of this product in the treatment of multiple myeloma, the patient's age is 86 years old.
Of  the 703 patients with multiple myeloma who underwent MM-009 and MM-010  study, 45% had age ≥65 years and 12% had age ≥75 years. There  was no significant difference in the proportion of patients ≥ 65 years  between the lenalidomide / dexamethasone group and the placebo /  dexamethasone group. Of the 353 patients receiving lenalidomide / dexamethasone, 46% had age ≥65 years. In  these two studies, patients with lenalidomide / dexamethasone were  found to be more likely to develop deep venous thrombosis, pulmonary  embolism, atrial fibrillation and renal failure in patients over 65  years of age than those in patients over 65 years of age Differences between the two. Because  elderly patients are more likely to have decreased renal function, so  in the choice of dose should be careful and renal function monitoring.